mesothelioma

NEWS: Peritoneal Surgeon Moves to Rutgers from University of Maryland

At the end of October of 2017, Dr. H. Richard Alexander, esteemed surgeon specializing in peritoneal mesothelioma, will be moving from his current institution, the University of Maryland, to Rutgers University in New Jersey.  His new position as Chief Surgical Officer will combine administrative as well as clinical duties. As such, Dr. Alexander will also […]


Anetumab Ravtansine Fails to Show Improvement of Progression-Free Survival in Mesothelioma

In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]


Mesothelioma Researcher Authors Journal Article on CAR T-cell Therapy

Mesothelioma researcher and Meso Foundation grant recipient Prasad S. Adusumilli, MD, FACS, FCCP, of the Memorial Sloan Kettering Cancer Center (MSKCC) was an author on the review article CAR T-cell therapy for lung cancer and malignant pleural mesothelioma recently published in Translational Research: The Journal of Laboratory and Clinical Medicine.
Dr. Adusumilli is a thoracic surgeon-scientist […]


New Book Serves as Resource for Mesothelioma Researchers

Joseph R. Testa, PhD, of the Fox Chase Cancer Center has edited a newly published book titled “Asbestos and Mesothelioma” to serve as a resource for researchers and medical professionals in the field. Mary Hesdorffer, NP, Executive Director at the Meso Foundation co-authored one of the book’s chapters.
More information about the book follows:
“Asbestos and Mesothelioma,” […]


Genentech Halts Avastin Approval Filing for Mesothelioma

In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]